| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Epidemiology (Dr. Stewart), The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD; the Departments of Neurology and Epidemiology and Social Medicine (Dr. Lipton), Albert Einstein College of Medicine and the Headache Unit, Montefiore Medical Center, Bronx, NY; Innovative Medical Research (Drs. Stewart, Lipton, and Chee), Inc., Baltimore, MD; Astra Zeneca (J. Sawyer), Willaston, Nantwick, Cheshire, UK; Jefferson Headache Center and Department of Neurology (Dr. Silberstein), Thomas Jefferson University, Philadelphia, PA.
Address correspondence and reprint requests to Dr. Walter F. Stewart, The Johns Hopkins School of Hygiene and Public Health, 615 North Wolfe Street, Baltimore, MD 21205.
BACKGROUND: Migraine is three times more common in women than men. There is a clinical impression that migraines are more common and severe around the time of menses.
OBJECTIVES: To determine 1) the distribution of headache attacks by day of the menstrual cycle in women with migraine, 2) if the excess occurrence varies by headache type, and 3) if headache features differ by time in the menstrual cycle.
METHODS: In a population-based sample, 81 menstruating women with clinically diagnosed migraine were enrolled in a 98-day diary study and completed a total of 7219 diary days. The daily diary was used to record the occurrence of menses, headache days, and, on days with headache, associated headache features (i.e., symptoms, quality-of-pain, attack duration, pain intensity, and disability at work, household work, and nonwork activities).
RESULTS: An excess risk of headache occurred perimenstrually and was highest on days 0 and 1 of the cycle (day 0 being the first day of menses). A significantly elevated risk of headache on days 0 and 1 was observed for migraine without aura (OR 2.04; 95% CI 1.49, 2.81) and for tension-type headache (OR 1.67; 95% CI 1.24, 2.25). Elevated risks were also observed in the 2 days before onset of menses for migraine without aura (OR 1.80; 95% CI 1.40, 2.30). A significantly lower risk was observed around the time of ovulation for all headaches (OR 0.44; 95% CI 0.27, 0.72). Few significant differences were observed in headache features (i.e., pain intensity, disability score, symptom score, headache duration) by day of the cycle overall or by headache type. Pain intensity was slightly greater for migraine headaches during the first 2 days of menses.
CONCLUSIONS: Attacks of migraine without aura, but not migraine with aura, were more likely to occur 2 days before onset of menses and on the first 2 days of menses. This study does not support the clinical notion that headaches, regardless of type, are more severe during the perimenstrual period compared to other times in the cycle. Although migraine headaches are significantly more painful during the first 2 days of menses, differences are small.–1523
This article has been cited by other articles:
|
|
 |
|
  B. L. Peterlin, G. Alexander, D. Tabby, and E. Reichenberger Oligomerization state-dependent elevations of adiponectin in chronic daily headache Neurology, May 13, 2008; 70(20): 1905 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. MacGregor, A. Frith, J. Ellis, L. Aspinall, and A. Hackshaw Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen Neurology, December 26, 2006; 67(12): 2154 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Brandes The influence of estrogen on migraine: a systematic review. JAMA, April 19, 2006; 295(15): 1824 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. MacGregor, A. Frith, J. Ellis, and L. Aspinall Predicting menstrual migraine with a home-use fertility monitor Neurology, February 8, 2005; 64(3): 561 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Loder Menstrual migraine: Timing is everything Neurology, July 27, 2004; 63(2): 202 - 203. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Silberstein, A. H. Elkind, C. Schreiber, and C. Keywood A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine Neurology, July 27, 2004; 63(2): 261 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. MacGregor and A. Hackshaw Prevalence of migraine on each day of the natural menstrual cycle Neurology, July 27, 2004; 63(2): 351 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Landy Migraine throughout the life cycle: Treatment through the ages Neurology, March 9, 2004; 62(90052): S2 - 8. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Nett, S. Landy, S. Shackelford, M. S. Richardson, M. Ames, and M. Lener Pain-Free Efficacy After Treatment With Sumatriptan in the Mild Pain Phase of Menstrually Associated Migraine Obstet. Gynecol., October 1, 2003; 102(4): 835 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Loder Prophylaxis of menstrual migraine with triptans: Problems and possibilities Neurology, December 10, 2002; 59(11): 1677 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.B. Lipton, R.K. Cady, W.F. Stewart, K. Wilks, and C. Hall Diagnostic lessons from the Spectrum Study Neurology, May 14, 2002; 58(90096): S27 - 31. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
